Table 3 Univariate and multivariate analyses of the duration of first-line TKI therapy.

From: Evaluation of the optimal timing of radiotherapy in EGFR-Mutant oligometastatic NSCLC through a retrospective analysis of treatment sequences and survival outcomes

Variable

Univariable

Multivariable

HR

95%CI

P

HR

95%

P

Age

< 60 vs. ≥60

1.13

0.69–1.85

0.619

   

Gender

Male vs. female

0.71

0.43–1.15

0.161

   

ECOG

0–1 vs. 2

1.66

0.60–4.60

0.33

   

EGFR mutation

EGFR 19del vs. 21L858R

0.79

0.47–1.34

0.386

   

EGFR 18 exon vs. 21L858R

2.35

0.89–6.19

0.083

   

EGFR 20 exon vs. 21L858R

1

0.35–2.85

0.998

   

Smoking status

No vs. Yes

0.97

0.59–1.59

0.911

   

T stage

1–2 vs. 3–4

2.09

1.24–3.54

0.01

2.5

1.40–4.59

0

N stage

0–1 vs. 2–3

0.78

0.37–1.65

0.517

   

M stage

No vs. Yes

0.74

0.43–1.27

0.278

   

Metastasis location

Brain metastases

No vs. Yes

1.3

0.73–2.30

0.369

   

Lung Radiation

No vs. Yes

0.46

0.26–0.81

0.01

0.4

0.21–0.71

0

TKI drugs

1 vs. 2

2.16

1.09–4.26

0.03

1.1

0.50–2.23

0.88

1 vs. 3

1.07

0.59–1.93

0.83

1

0.57–1.84

0.95

Initial chemotherapy

No vs. Yes

0.91

0.55–1.48

0.695

   

Patterns of progression

Local vs. Distant

1.08

0.60–1.93

0.8

   
Back to article page